Argos Therapeutics Inc., today announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy, or treatment to shrink a tumor before surgery, in patients with localized renal-cell carcinoma. The study is being conducted at Roswell Park Cancer Institute and is designed to enroll a maximum of 10 patients who will be treated with AGS-003 before nephrectomy in order to assess immune-system response and tumor effects.

One patient’s journey undergoing three Blood and Marrow Transplants (BMT) while struggling with myelofibrosis, a bone marrow disease that can lead to acute leukemia, has provided new insights into mechanisms that may reduce some negative transplant side effects.

Russell Salvatore is providing free TV service for patients and their families as the result of a generous donation to Roswell Park Cancer Institute. The prominent Buffalo businessman’s gift of $400,000 will give all patients admitted at Roswell Park a sense of comfort and allow them to enjoy television free-of-charge throughout their hospital stay.

Vishala Neppalli, MD, Assistant Professor of Oncology in the Department of Pathology and Laboratory Medicine, is honored as a mentor for a second consecutive year with an American Society of Hematology (ASH) Visitor Training Award.

It has long been known that rates of breast and cervical cancer screening among Latinas are low compared to rates for U.S. women overall. A study led by researchers at Roswell Park Cancer Institute (RPCI) found that age and fear of cancer diagnosis are among the reasons why Latina women do not continue participation following breast and cervical cancer education programs.

For patients with leukemia, lymphoma, and other blood cancers, a blood or marrow transplant (BMT) can be a potential cure.